ES2590340T3 - SlpA como herramienta para la tecnología recombinante de proteínas y enzimas - Google Patents

SlpA como herramienta para la tecnología recombinante de proteínas y enzimas Download PDF

Info

Publication number
ES2590340T3
ES2590340T3 ES09006933.7T ES09006933T ES2590340T3 ES 2590340 T3 ES2590340 T3 ES 2590340T3 ES 09006933 T ES09006933 T ES 09006933T ES 2590340 T3 ES2590340 T3 ES 2590340T3
Authority
ES
Spain
Prior art keywords
slpa
polypeptide
protein
prot
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09006933.7T
Other languages
English (en)
Spanish (es)
Inventor
Elke Faatz
Peter Schaarschmidt
Urban Schmitt
Christian Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2590340T3 publication Critical patent/ES2590340T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
ES09006933.7T 2008-05-26 2009-05-25 SlpA como herramienta para la tecnología recombinante de proteínas y enzimas Active ES2590340T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08009537A EP2127678A1 (en) 2008-05-26 2008-05-26 SlpA as a tool for recombinant protein and enzyme technology
EP08009537 2008-05-26

Publications (1)

Publication Number Publication Date
ES2590340T3 true ES2590340T3 (es) 2016-11-21

Family

ID=39590486

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09006933.7T Active ES2590340T3 (es) 2008-05-26 2009-05-25 SlpA como herramienta para la tecnología recombinante de proteínas y enzimas

Country Status (6)

Country Link
US (2) US8263086B2 (enExample)
EP (2) EP2127678A1 (enExample)
JP (1) JP5611540B2 (enExample)
CN (1) CN101591665B (enExample)
CA (1) CA2667177C (enExample)
ES (1) ES2590340T3 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617731A1 (en) * 2012-01-19 2013-07-24 Roche Diagnostics GmbH Soluble immunoreactive Treponema pallidum TpN47 antigens
EP2706115A1 (en) 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
EP2827146A1 (en) * 2013-07-18 2015-01-21 Roche Diagnostics GmbH Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies
HUE038721T2 (hu) * 2013-12-19 2018-11-28 Intervet Int Bv Javított diagnosztikus teszt CSFV antitestek számára
EP2913338A1 (en) * 2014-02-28 2015-09-02 Roche Diagniostics GmbH Soluable and immunoreactive variants of HTLV capsid antigen p24
WO2016064643A1 (en) * 2014-10-24 2016-04-28 University Of Florida Research Foundation, Incorporated Lactobacillus acidophilus surface layer protein a (slpa) as a therapeutic agent for the treatment of inflammatory diseases
US10118956B2 (en) 2014-12-01 2018-11-06 Pfenex Inc. Fusion partners for peptide production
ES3050636T3 (en) 2016-05-31 2025-12-22 Hoffmann La Roche Method for serological detection of viral antigens
KR102156994B1 (ko) 2016-05-31 2020-09-17 에프. 호프만-라 로슈 아게 Hcv 코어 항원의 신속한 검출을 위한 전처리 방법
WO2018141768A1 (en) 2017-02-02 2018-08-09 Roche Diagnostics Gmbh Immunoassay using at least two pegylated analyte-specific binding agents
CN110996986B (zh) * 2017-07-27 2024-07-19 豪夫迈·罗氏有限公司 Hcv抗原的多表位融合蛋白及其用途
EP3957995A1 (en) * 2018-11-19 2022-02-23 Bioaster Methods and reagents for multiplex binding experiments
EP4413020A4 (en) * 2021-10-05 2025-12-17 Viro Res Llc Lateral flow test for herpes simplex virus type 1 and 2
WO2025098623A1 (en) 2023-11-09 2025-05-15 Roche Diagnostics Gmbh Transglutaminase substrates for labeling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
KR100702373B1 (ko) 2001-06-22 2007-04-02 에프. 호프만-라 로슈 아게 레트로바이러스 표면 당단백질을 함유하는 가용성 복합체
JP4871960B2 (ja) * 2006-01-03 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー 優れたシャペロン活性およびフォールディング活性を有するキメラ融合タンパク質

Also Published As

Publication number Publication date
EP2127679A1 (en) 2009-12-02
JP2009284902A (ja) 2009-12-10
CN101591665B (zh) 2016-08-31
EP2127678A1 (en) 2009-12-02
CA2667177A1 (en) 2009-11-26
JP5611540B2 (ja) 2014-10-22
CN101591665A (zh) 2009-12-02
US8263086B2 (en) 2012-09-11
US20090291892A1 (en) 2009-11-26
US20120308994A1 (en) 2012-12-06
EP2127679B1 (en) 2016-06-29
US8790659B2 (en) 2014-07-29
HK1138620A1 (zh) 2010-08-27
CA2667177C (en) 2017-08-15

Similar Documents

Publication Publication Date Title
ES2590340T3 (es) SlpA como herramienta para la tecnología recombinante de proteínas y enzimas
ES2333108T3 (es) Utilizacion de chaperonas fkbp como herramienta de expresion.
ES2368624T3 (es) Detección de infecciones primarias por patógenos.
ES2375863T3 (es) Prote�?na de fusión quimérica con actividades de chaperón y de plegamiento superiores.
CN108699104B (zh) 具有转谷氨酰胺酶识别位点的fkbp结构域
US8551696B2 (en) Rubella E1 envelope protein variants and their use in detection of anti-rubella antibodies
EP1780282B1 (en) Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies
ES2356383T3 (es) Expresión recombinante de variantes de proteína de cubierta de rubeola e1 como proteínas de fusión chaperonas, y utilización de las mismas en la detección de anticuerpos anti-rubeola.
HK1138620B (en) Slpa as a tool for recombinant protein and enzyme technology
HK1148026B (en) Novel rubella e1 envelope protein variants and their use in the detection of antirubella antibodies